Sensible Biotechnologies develops mRNA manufacturing technology for therapeutics and vaccines. The company aims to produce non-immunogenic, pure, and highly functional mRNA to accelerate the development of next-generation mRNA medicines.

Sensible Biotechnologies

At Sensible Biotechnologies, we are building best-in-class platform for manufacturing of high-quality mRNA in a scalable way to unlock the next generation of mRNA medicines and strengthen the global biosecurity.

Our Founders Marian Kupculak and Miroslav Gasparek talked with Forbes Slovensko (Forbes Slovakia) about our work on building the next-generation mRNA platform to unlock and accelerate development of novel mRNA medicines. 

They outlined our vision for completely differentiated platform for mRNA manufacturing -  and why it is crucial for both advent of novel mRNA medicines and for enhancing of the global biosecurity.

They also talked about our product development, business model, and partnering with big biotech companies. They also talked about our team and the importance of having the backing of sector-specific institutional investors and supportive angels. 

Stay tuned for what is next!  

You can read the article on the link below (in Slovak)
https://lnkd.in/gqzNXT_U

#Sensible #SensibleBio #mRNA #mRNAmadebetter #Forbes #30under30 #biomanufacturing #biosecurity

Our Co-Founder and CEO Miroslav Gasparek and our Head of Science Leanne Minall are attending the mRNA-Based Therapeutics Summit in Boston on July 29-31.

We have many exciting updates to share at Sensible Biotechnologies, so please let get in touch if you would like to learn more about our platform enabling the next generation of mRNA medicines by making high-quality mRNA in a cost-effective and scalable way.

#sensible #sensiblebio #mRNAmadebetter #mRNASummit #WorldRNA #mRNATherapeutics #mRNAVaccines

We are excited that Sensible Biotechnologies was awarded a prize of $10,000 at the BARDA VITAL Global Health Security Symposium pitch competition organized by VITAL – A BARDA BAN Hub recognition of our innovative approach to advancing global health security. Also, massive congratulations to Cutanos GmbH and Avocet Bio GmbH, who won the first and second place respectively.

At Sensible , we are committed to building the next-generation platform to produce high-quality mRNA in a cost-effective and scalable manner. Our mission is to enable the development of the next generation of safer, more effective, and accessible mRNA medicines, while strengthening the global biomanufacturing infrastructure, and enhancing global biosecurity.

The BARDA VITAL Global Health Security Symposium was a fantastic event, bringing together leading experts, researchers, and professionals from around the world to discuss the latest advancements in pandemic preparedness and response, including speakers from institutions such as World Health Organization, SPRIND - Bundesagentur für Sprunginnovationen, Biomedical Advanced Research and Development Authority (BARDA) and European Health Emergency Response Authority. 

We are grateful for the opportunity to spend time at Berlin Institute of Health at Charité - Universitätsmedizin Berlin at the Rahel Hirsch Center. Many thanks to Steven Laken and Raquel Riera from Advise Connect Inspire, LLC, Marc Filerman, Deborah Lee and Annika Pierson from Start2 Group, as well as to Rachel Rath, Ashim Subedee, and Mary Larkin from J&J and BARDA. 

Our team at Sensible is looking forward to continuing our work in strengthening global biomanufacturing infrastructure and enhancing biosecurity. Stay tuned! 

#sensible #mRNAmadebetter #biomanufacturing #biosecurity #GlobalHealth #HealthSecurity #Vaccines #Therapeutics #Biotech

We are thrilled to announce that we have been selected as a finalist to pitch at the BARDA VITAL Global Health Security Symposium on June 27 in Berlin.

This event focuses on visionary advancements in vaccine and therapeutics innovation, and medical countermeasures aimed at enhancing pandemic preparedness and response for a safer future. We are excited to talk about how Sensible's cell-based platform can enable cost-effective and scalable production of safe mRNA therapeutics and vaccines to enhance the global #biosecurity landscape and strengthen #bioeconomy across the globe.

Our CEO and Co-Founder Miroslav Gasparek will showcase how Sensible's work on mRNA can  critical health challenges. This event brings together the brightest minds in the field, and we are honored to be part of it.

Register now: 
 https://lnkd.in/dH4BWcKF

Be a part of the future of healthcare innovation — we hope to see you there!
#DigitalHealth #Vaccines #Therapeutics #GlobalHealth #Biotech
Biomedical Advanced Research and Development Authority (BARDA) VITAL – A BARDA BAN Hub

We are grateful to University of Oxford, Department of Engineering Sciencet for sharing the story about Imperial College London Emerging Alumni Leader Award 2024, which was awarded to our CEO and Co-Founder, Miroslav Gasparek. 

We are very excited about the progress of our work on turning living cells into efficient factories for high-quality mRNA to enable safe, effective, and affordable mRNA medicines, while strengthening the global #biosecurity through providing robust mRNA biomanufacturing #infrastructure. Stay tuned for more exciting news! 

Many thanks to Julie Meikle for her fantastic article.

Read more on the link below: 
https://lnkd.in/e5QjPf9x

#sensible #sensiblebio #mRNAmadebetter #oxford #oxfordengsci

As the alum of the Nucleate’s flagship Activator programme, Sensible Biotechnologies  is very excited to sponsor The Forum, the premier forum that provides opportunity for the important conversations about the life science industry in the UK.

Our CEO and Co-Founder Miroslav Gasparek will discuss the story of Sensible and the early-stage life science entrepreneurship with Vishal Gulati, Managing Partner at Recode Ventures, one of the icons of early-stage and founder-friendly life-science investing, and with Amit Halkhoree, Nucleate UK’s National Director of Communications. We are excited to listen to and learn from leading figures in the European and UK life science ecosystem, including Lorenz Mayr, Molly Stevens, David Roblin and many others. 

Many thanks to the Nucleate UK team and other co-sponsors for making this event possible!

#nucleateuk #nucleate #theforum #sensible #founderledbio

We are excited to announce that our Founders Miroslav Gasparek and Marian Kupculak were elected to Forbes 30 Under 30 Europe Class of 2024 in Science & Healthcare category! 

#ForbesUnder30 #Forbes #SensibleBio #sensible #mRNAmadebetter #techbio #mariankupculak #miroslavgasparek

After a year, we are back in Basel, where our CEO Miroslav Gasparek is moderating a panel "Manufacturing Growing Pains - What are The Bottlenecks in RNA Manufacturing" at RNA Leaders conference. 

Joining Miro for this panel will be a suite of leading mRNA experts: 
- Brendan Fish,  Director of Biologics & RNA Centre of Excellence, CPI 
- Antoine Maupu, VP of Manufacturing, Moderna 
- François HALLAC, Post-Doc Manufacturing Systems, King's College London 
- Nick Lench,  Executive Director, The MRC NATA - Nucleic Acid Therapy Accelerator  

Are you going to be in Basel on Wednesday or Thursday? Definitely come to speak with Marian Kupculak and Miro about cell-based platform for production of high-quality mRNA in a cost-effective and scalable way to enable the next generation of mRNA medicines we are building at Sensible Biotechnologies  Biotechnologies. 

#SensibleBio #rnaleaders #RNA #mRNA #biotech #mRNAmadebetter

An interview and podcast about Sensible Biotechnologies in Slovak Daily Denník SME

Our CEO and Co-Founder Miroslav Gasparek  talked about our work on building cell-based mRNA platform to enable the future mRNA medicines for major Slovak newspaper, Dennik SME.

We are glad we could discuss how our bioengineering team led by  Marian Kupculak engineers cells to make best-in-class mRNA molecules, while expanding the scale and reducing the cost of mRNA manufacturing. Our objective is to enable the next-generation of mRNA medicines, while becoming one of the pillar of global biosecurity infrastructure. 

Miro also discussed early-stage fundraising for an early-stage biotech startup, the investor diligence Sensible had to go through, our partnership with Ginkgo Bioworks, Inc., and building global biotech company with presence in the US, UK, and Slovakia

We still have a long way to go - but we will do all we can to bring high-quality mRNA to many patients across the globe. 

Thanks to Denisa Prokopčáková for all the great questions.

You can find the link to the interview below (in Slovak): 
https://lnkd.in/eRBQfzr4

The link to podcast is below as well (in Slovak, too):
https://lnkd.in/eHHYaYCj

#sensiblebiotechnologies #mRNA #mRNAmadebetter #DennikSME #biotech

Sensible Biotechnologies at mRNA-Based Therapeutics Summit Europe 2024

We are excited to be joining a number of European leaders in the field of mRNA medicines in these two days in Berlin at mRNA-Based Therapeutics Summit Europe 2024 by Hanson Wade Group.

Our Chief Executive Officer Miroslav Gasparek and our Chief Scientific Officer Marian Kupculak are excited to meet and tell you more about how we are unlocking the next-generation of mRNA medicines by developing our cell-based platform for production of high-quality mRNA in a cost-effective and scalable way. We are exploring synergies with increasing number of industrial partners and academic collaborators. Do you want to build with Sensible? Let me and Marian know and we can talk about our synergies.

You can also read an article in Forbes by John Cumbers that nicely summarizes our mission: https://lnkd.in/e4XTQMJ5

Learn more about Sensible Biotechnologies here: https://www.sensible.bio/

#mRNA #mRNAmadebetter #sensible #sensiblebio

BIO:SENSIBLE

Sensible Biotechnologies

Analysis Not Available